Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00741910 · ClinicalTrials.gov registry record · Phase 2
Extension Study of Semapimod 60 mg IV x 3 Days
A Phase 2 study, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT00741910 is a Phase 2 study that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 15 participants.
The verdict
NCT00741910, a Phase 2 study, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
Study CNI-1493-CD06 is an open, single-arm extension studies to CD03 and CD05. CDAI is the only efficacy measure assessed in this study. The safety of multiple courses of semapimod is to be determined by the incidence of clinical and laboratory adverse events.
Interventions
- DRUG Semapimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2003-07 |
| Est. Completion | 2006-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00741910
The ClinicalTrials.gov registry entry for NCT00741910 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Semapimod is the first listed.
NCT00741910 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00741910 about?
NCT00741910 is a clinical study titled "Extension Study of Semapimod 60 mg IV x 3 Days". Study CNI-1493-CD06 is an open, single-arm extension studies to CD03 and CD05. CDAI is the only efficacy measure assessed in this study. The safety of multiple courses of semapimod is to be determined by the incidence of clinical and laboratory adverse events.
What is the current status of trial NCT00741910?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2003-07. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00741910?
The interventions under investigation include: Semapimod (DRUG).
Who is sponsoring clinical trial NCT00741910?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.